ARPHA Preprints

PENSOFT

PREPRINT

Author-formatted, not peer-reviewed document posted on 16/07/2025

DOI: https://doi.org/10.3897/arphapreprints.e165146

Strategic Proposal for Selective Awakening and Targeted Elimination of Latent Viruses Through Molecular Pathway Disruption

Priscila Gil

ARPHA Preprints *Author-formatted, not peer-reviewed document posted on 16/07/2025*. DOI: https://doi.org/10.3897/arphapreprints.e165146

Strategic Proposal for Selective Awakening and Targeted Elimination of Latent Viruses Through Molecular Pathway Disruption

Priscila Gil ‡

‡ Independent Researcher, Leiria, Portugal

Corresponding author: Priscila Gil (priscila.gil83@gmail.com)

Reviewable v 1

Abstract

Latent viral infections, such as those caused by Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), and Epstein-Barr Virus (EBV), remain a major obstacle to achieving complete viral eradication. These pathogens establish dormancy within host cells, effectively evading immune detection and undermining standard antiviral therapies. This research proposal outlines a three-phase strategy that integrates nanotechnology and molecular biology to selectively reactivate latent viruses and eliminate them through targeted capture and neutralization mechanisms. By employing biomimetic nanostructures and phase-specific activation triggers, this approach seeks to minimize off-target effects and collateral damage, offering a controlled and replicable platform for treating chronic viral infections.

Keywords

Latent viruses, Molecular disruption, Viral eradication, Public health

Overview and background

Latent viruses present a significant challenge to global health due to their ability to persist within host cells in a dormant state, undetected by immune surveillance (Ferrari 2005). Current antiviral therapies often suppress viral replication but fail to fully eradicate latent reservoirs, especially in infections such as HIV and HSV (White et al. 2012). The persistence of these reservoirs necessitates lifelong treatment regimens, which may lead to resistance and limited patient adherence (Darcis et al. 2017). Recent advancements in molecular biology and nanotechnology suggest that it is feasible to selectively reactivate latent viruses under controlled conditions, thereby exposing them to targeted therapeutic interventions. This proposal builds upon existing literature on viral latency mechanisms and nanomedical strategies (White et al. 2012) for intracellular targeting, aiming to

© Gil P. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

develop a replicable framework for safe and effective viral clearance without inducing widespread systemic effects.

Objectives

This project aims to develop a structured and replicable framework for the controlled reactivation and elimination of latent viruses. By integrating principles from nanotechnology and molecular virology, the goal is to design smart biomimetic nanostructures capable of reactivating latent viruses in a targeted manner and facilitating their capture and neutralization (Nakamura et al. 2022). The proposed approach seeks to address current limitations in chronic viral infection management by offering a pathway toward definitive clearance rather than lifelong viral suppression.

Impact

If successfully implemented, this strategy could redefine the therapeutic landscape for chronic viral infections by shifting the paradigm from lifelong suppression to targeted eradication (Chun and Fauci 2012). The ability to selectively awaken and eliminate latent viruses would not only improve patient outcomes and reduce long-term treatment burdens but also open new frontiers in personalized virotherapy. The integration of nanotechnology with molecular targeting presents a scalable and adaptable platform that could be tailored to various viral families, potentially transforming public health approaches to persistent viral threats.

Methodology

The proposed strategy involves three sequential phases. First, targeted molecular triggers will be designed to induce the reactivation of latent viruses under controlled conditions, minimizing the risk of systemic immune activation. Second, reactivated viral particles will be intercepted using engineered nanostructures cloaked with host-derived membranes, allowing for biomimetic recognition and neutralization. Finally, these virus-bound nanostructures will be safely cleared from the system via hepatic or renal pathways. The methodology leverages advances in virology, nanomaterials, and intracellular targeting (Nakamura et al. 2022,White et al. 2012) and is intended to be tested initially through in vitro models before proceeding to in vivo applications.

Conclusion

This proposal outlines a novel, three-phase strategy for the selective awakening and elimination of latent viruses through molecular pathway disruption, addressing the persistence challenge described by Ferrari 2005. By combining nanotechnology with

phase-specific activation and viral targeting mechanisms, the approach offers a promising alternative to conventional antiviral treatments. It responds to a well-documented gap in current therapeutic strategies, where latent viral reservoirs remain difficult to eliminate (Siliciano and Greene 2011), and provides a structured framework for future experimental validation. Further research will be required to evaluate its full potential and translate this concept into practical therapeutic applications.

Hosting institution

Independent researcher

Conflicts of interest

The authors have declared that no competing interests exist.

References

- Chun T-, Fauci AS (2012) HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 26 (10): 12611268. https://doi.org/10.1097/QAD.0b013e328353f3f1
- Darcis G, Van Lint C, Van Driessche B (2017) HIV latency: should we shock or lock? Trends in Immunology 38 (3): 217-228. https://doi.org/10.1016/j.it.2016.12.003
- Ferrari M (2005) Cancer nanotechnology: Opportunities and challenges. Nature Reviews Cancer 5 (3): 161-171. [In English]. https://doi.org/10.1038/nrc1566
- Nakamura T, Elfainatur Haloho SE, Harashima H (2022) Intravenous liposomal vaccine enhances CTL generation, but not until antigen presentation. Journal of Controlled Release 343: 1-12. https://doi.org/10.1016/j.jconrel.2022.01.020
- Siliciano RF, Greene WC (2011) HIV latency. Cold Spring Harbor Perspectives in Medicine 1 (1): a007096. https://doi.org/10.1101/cshperspect.a007096
- White DW, Beard RS, Barton ES (2012) Immune modulation during latent herpesvirus infection. Immunological Reviews 245 (1): 189-208. https://doi.org/10.1111/j.1600-065X.2011.01074.x